Carlo Tondini - Concepedia

Author

Carlo Tondini

Also Known As

Antonio Maconi, C Tondini, C. A. Tondini, C. Tondini, C.A. Tondini, CA Tondini, CARLO TONDINI, Carlo A Tondini, Carlo A. Tondini, Carlo Alberto Tondini

241

Publications

12.5K

Citations

H-Index

106

Concepts

All Affiliations

Ospedale Papa Giovanni XXIII Fondazione IRCCS Istituto Nazionale dei Tumori European Institute of Oncology Dana-Farber Cancer Institute Istituti di Ricovero e Cura a Carattere Scientifico

About

Carlo Tondini is an author at Ospedale Papa Giovanni XXIII specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	45	5.7K
2	Public Health	8	8	181
3	Health Sciences	3	3	52
4	Engineering	1	1	45
5	Allergy	1	1	13

Carlo Tondini

Publications

9.6K

Citations

H-Index

Page 1

	Year	Citations
A predictive model for aggressive non-Hodgkin's lymphoma Margaret A. Shipp, David P. Harrington, J R Anderson, Lymphoid NeoplasiaAggressive Non-hodgkinMedicinePathologyLymphatic Disease	1993	3.5K
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer Olivia Pagani, Meredith M. Regan, Barbara Walley, New England Journal of Medicine	2014	738
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer Prudence A. Francis, Olivia Pagani, Gini F. Fleming, New England Journal of Medicine	2018	646
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial Viviana Galimberti, Bernard F. Cole, Giuseppe Viale, The Lancet Oncology Surgical OncologyBreast OncologyMedicineIbcsg 23-01Breast Cancer	2018	533
Cancer Risks Associated With Germline<i>PALB2</i>Pathogenic Variants: An International Study of 524 Families Xin Yang, Goska Leslie, Alicja Doroszuk, Journal of Clinical Oncology	2019	393
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials Meredith M. Regan, Prudence A. Francis, Olivia Pagani, Journal of Clinical Oncology	2016	178
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials Jürg Bernhard, Weixiu Luo, Karin Ribi, The Lancet Oncology Patient-reported OutcomesBreast OncologyPhase 3MedicineRandomised Trials	2015	172
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Carlo Tondini, Daniel F. Hayes, Rebecca Gelman, PubMed Clinical CourseMetastatic Breast CancerBreast OncologyCancer DetectionMedicine	1988	159
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT Olivia Pagani, Prudence A. Francis, Gini F. Fleming, Journal of Clinical Oncology	2019	143
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials Olivia Pagani, Barbara Walley, Gini F. Fleming, Journal of Clinical Oncology	2022	141

Page 1